Company Bachem Holding AG Swiss Exchange

Equities

BANB

CH0012530207

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Inactive Instrument

Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

Number of employees: 2,006

CHF in Million	2022	Weight	2023	Weight	Delta
Commercial Active Pharmaceutical Ingredients 53.5 %	299	56.2 %	309	53.5 %	+3.43%
Clinical Medicines Category Development 39.4 %	186	35.0 %	228	39.4 %	+22.43%
Research and Specialties 7.1 %	47	8.9 %	41	7.1 %	-13.45%

CHF in Million	2022	Weight	2023	Weight	Delta
Europe / Asia 62.7 %	316	59.5 %	362	62.7 %	+14.45%
North America 37.3 %	215	40.5 %	215	37.3 %	-0.06%

Managers	Title	Age	Since
Thomas Meier CEO	Chief Executive Officer	56	18-12-31
Alain Schaffter DFI	Director of Finance/CFO	47	21-01-31
Ralph Schönleber CTO	Chief Tech/Sci/R&D Officer	-	02-12-31
Roland Schürmann COO	Chief Operating Officer	60	19-12-31
Günther Loidl CTO	Chief Tech/Sci/R&D Officer	54	14-12-31
Viviane Minden HRO	Human Resources Officer	-	-
Chris McGee PRN	Corporate Officer/Principal	-	11-02-28
Torsten Wohr SAM	Sales & Marketing	56	21-12-31
Jean-Marc Fellay HRO	Human Resources Officer	-	-
Manuela Schneider-Höfferer SAM	Sales & Marketing	-	19-12-31

Members of the board	Title	Age	Since
Peter Grogg BRD	Director/Board Member	82	-
Kuno Sommer CHM	Chairman	68	12-04-24
Nicole Grogg Hötzer BRD	Director/Board Member	51	11-04-12
Helma Wennemers BRD	Director/Board Member	55	14-04-27
Steffen Lang BRD	Director/Board Member	57	20-04-21
Alex Faessler BRD	Director/Board Member	69	21-04-27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	75,000,000	70,735,600 ( 94.31 %)	26,355 ( 0.0351 %)	94.31 %

Name	Equities	%	Valuation
Peter Grogg 51.94 %	38,957,455	51.94 %	3 737 M CHF
Grogg Family 5.404 %	4,053,170	5.404 %	389 M CHF
VV Vermögensverwaltung AG 4.848 %	3,636,000	4.848 %	349 M CHF
Juno Investment Partners 0.5723 %	429,247	0.5723 %	41 M CHF
ÖKOWORLD LUX SA 0.4520 %	339,000	0.4520 %	33 M CHF
Union Bancaire Privée, UBP SA 0.3694 %	277,038	0.3694 %	27 M CHF
DNCA Finance SA 0.2329 %	174,647	0.2329 %	17 M CHF
Banque Cantonale de Genève (Investment Management) 0.1960 %	147,030	0.1960 %	14 M CHF
Caixabank Asset Management SGIIC SA 0.1398 %	104,878	0.1398 %	10 M CHF
Aargauische Kantonalbank (Invt Mgmt) 0.1090 %	81,752	0.1090 %	8 M CHF

Name	Equities	%	Valuation
BACHEM HOLDING AG 0.04%	28,800	0.04%	2,762,651 $

Bachem Holding AG

Hauptstrasse 144

4416, Bubendorf

+41 58 595 2021

http://www.bachem.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research